Search
Sumario de resultados
TIpos de contenido
Fecha
-
AllyIMCD España Especialidades Químicas, S.A
IMCD es un distribuidor y formulador líder de productos químicos e ingredientes especializados. Aportamos innovación para un mundo más saludable al proporcionar materiales y excipientes con una cadena
-
New#NewAseBioMember| "We also see AseBio as an opportunity to stay aligned with regulatory, s...
Meet our new member Disrupt Therapeutics. We spoke with Patrick Tresserras, CEO y Maria Gallo COO de Disrupt Therapeutics
-
New#NewAseBioMember | "We see AseBio as the go-to platform for fostering synergies within Spa...
Meet our new member Nuage. We spoke with Stuart Hughes, CEO
-
CompanyGOODGUT
-
New#NewAseBioMember | “AseBio is a key platform that brings together the main players in the ...
Meet our new member Melius Organics. We spoke with Jordi Mestre, CEO & Cofundador.
-
-
NewR&D investment in the biotech sector grows by 5.2% to 1,282 million euros
In 2023, the activity of biotech companies in Spain generated more than 13,000 million euros of income, which represents 1.1% of the national GDP.
-
Press releaseR&D investment in the biotech sector grows by 5.2% to 1,282 million euros
In 2023, the activity of biotech companies in Spain generated more than 13,000 million euros of income, which represents 1.1% of the national GDP. After an exceptional 2023 for the sector in terms of
-
New#NewAseBioMember | “Being a member of AseBio represents a great opportunity to increase ou...
Meet our new member Airway Shield. We spoke with Julio Alonso Babarro, CEO.
-
NewAbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous ...
These results support ibrilatazar as a potential backbone therapy for patients with one of the most common subtypes of lung cancer worldwide, addressing a high- unmet need.
-
New#NewAseBioMember | “AseBio is a key platform for connecting with other biotech players in ...
Meet our new member CIMAB. We spoke with Agustín García-Peiró, CEO and Founder.
-
NewTheriva™ Biologics Announces Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clini...
Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical
-
NewGenetics Becomes an Ally for Healthcare Professionals
Personalized medicine is no longer a promise—it's a reality, with genetics as its key ally. To bring this knowledge into everyday clinical practice, N·GENE was created: a platform that translates
-
NewBCN HEALTH publishes a study highlighting the substantial healthcare costs associated with...
BCN HEALTH has published the study ‘Hepatocellular carcinoma: what are the differential costs compared to the general population?’ in the Journal of Medical Economics, a peer-reviewed journal
-
NewAccelerating molecular discovery using an in silico design platform
Join our free event on Tuesday, July 8th at the Parque Científico de Barcelona for an extended version of our Lunch and Learn series where we will introduce the diverse capabilities of Schrödinger’s
-
CompanyCOLFEED4PRINT
-
NewNatac wins the 'Extremadura Company Award' granted by the Ros Group
The award recognises the company's track record, innovation and contribution to the economic and social development of Extremadura.
-
New#NewAseBioMember | “#NewAseBioMember | “AseBio is the meeting point for all companies that...
Meet our new member Microviable Therapeutics . We sponke with Claudio Hidalgo Cantabrana, CEO.
-
CompanyNUAGE THERAPEUTICS
-
NewBioDuro hosts webinar: "Exploring Peptide In-Vitro ADME Properties – From Natural Peptides...
The webinar exploring the in-vitro ADME (Absorption, Distribution, Metabolism, and Excretion) properties of peptide therapeutics.
-
NewUniversity of Barcelona Science Park ecosystem holds steady with €124 million in investmen...
The 86 spin-offs, start-ups and scale-ups operating in the PCB collectively secured €124.7 million in funding in 2024, which is a substantial rise on the €85.4 million raised in 2023.